Submit Modified Informed Consent Form with details: CDSCO Panel Tells Sanofi om Multiple Sclerosis Drug Tolebrutinib Dr. Divya Colin21 Jan 2024 6:00 PM ISTNew Delhi: Reviewing the Phase III clinical study protocol of Tolebrutinib presented by the drug major Sanofi, the Subject Expert Committee (SEC)...
CDSCO Panel Approves Sanofi's Protocol Amendment proposal for COPD drug Itepekimab Dr. Divya Colin21 Jan 2024 5:00 PM ISTNew Delhi: The Subject Expert Panel (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Sanofi's...
USFDA updates Sanofi Dupixent label for atopic dermatitis Ruchika Sharma18 Jan 2024 3:00 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent (dupilumab) in atopic dermatitis,...
Sanofi names Brian Foard as head of Specialty Care Global Business Unit Ruchika Sharma10 Jan 2024 1:30 PM ISTParis: Brian Foard, a healthcare industry veteran and Sanofi leader in the U.S., has been named Head of the company's Specialty Care Global...
AstraZeneca-Sanofi Beyfortus gets nod for RSV disease prevention in infants in China Ruchika Sharma2 Jan 2024 3:06 PM ISTChina: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of...
Lupin to buy established products portfolio in Europe, Canada from Sanofi for Rs 91 crore Ruchika Sharma23 Dec 2023 3:47 PM ISTUnder the agreement, Lupin will acquire brands AARANE in Germany and NALCROM in Canada and the Netherlands.
Sanofi India names Himanshu Bakshi as General Manager for Consumer Healthcare Business Roshni Dhar20 Dec 2023 5:51 PM ISTSanofi India Limited (SIL) has announced the appointment of Himanshu Bakshi as General Manager for its Consumer Healthcare (CHC) business, effective...
CDSCO Panel revises warning statement of Sanofi's antidiabetic FDC Insulin Glargine plus Lixisenatide Dr. Divya Colin13 Dec 2023 6:00 PM ISTNew Delhi: Approving the amendment in the warning statement for Sanofi's Fixed Ratio Combination of Insulin Glargine 100U/mL plus Lixisenatide 50...
Sanofi terminates deal to exclusively license Maze Therapeutics Pompe disease drug Ruchika Sharma12 Dec 2023 2:30 PM ISTWashington: Sanofi has said it was terminating a deal to exclusively license a drug that Maze Therapeutics is developing to treat Pompe disease...
Sarclisa plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone: Sanofi Ruchika Sharma11 Dec 2023 2:30 PM ISTParis: Sanofi has announced that the Phase 3 trial investigating Sarclisa (isatuximab) in combination with carfilzomib, lenalidomide and...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline Ruchika Sharma8 Dec 2023 1:30 PM ISTNew Delhi: Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it...
